Physician profile
Jonathan Beecher
NPI 1073364519
$6,706.33
in general payments reported to CMS, 2019-2025
24 companies · $4,123 in 2025
The $4,123 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,583 · 2025: $4,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,694 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,694.18 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,048.30 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $903.60 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $704.52 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $673.63 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $599.79 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $596.59 | 2024-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $447.02 | 2024-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $370.23 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $347.93 | 2024-2025 | Spravato |
| Alkermes, INC. | $241.37 | 2024-2025 | Aristada, Aristada Initio, Vivitrol |
| Idorsia Pharmaceuticals US INC | $158.22 | 2024 | Quviviq |
| Axsome Therapeutics, INC. | $112.13 | 2024-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $87.36 | 2024-2025 | Trintellix |
| Bausch Health US, LLC | $87.03 | 2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $67.18 | 2024-2025 | Sublocade |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $49.48 | 2024-2025 | Qelbree |
| Corium, LLC | $48.30 | 2024-2025 | Azstarys |
| Mallinckrodt Hospital Products INC. | $33.29 | 2025 | Acthar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $30.75 | 2024 | Rejoyn |
| Janssen Scientific Affairs, LLC | $21.83 | 2024 | Spravato |
| Luye Pharma (USA) LTD. | $21.30 | 2025 | Erzofri Extended-Release |
| Livanova USA, INC. | $20.22 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Collegium Pharmaceutical, INC. | $19.29 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $16.97 | 2024 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Beecher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.